In addition, after analyzing safety, efficacy, and PK data, BI terminated the phase I trial of BI-1701963 alone or in combination with the MEK inhibitor BI-3011441 (NCT04835714) and the phase I trial of BI-1701963 in combination with irinotecan in patients with advanced colorectal cancer with KRAS mutation (NCT04627142). The gene discussed is KRAS; the disease is colorectal cancer.